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ABSTRACT
Introduction Survivors of acute pancreatitis (AP) have 
shorter overall survival and increased incidence of new- onset 
cardiovascular, respiratory, liver and renal disease, diabetes 
mellitus and cancer compared with the general population, but 
the mechanisms that explain this are yet to be elucidated. Our 
aim is to characterise the precise nature and extent of organ 
dysfunction following an episode of AP.
Methods and analysis This is an observational prospective 
cohort study in a single centre comprising a University 
hospital with an acute and emergency receiving unit and 
clinical research facility. Participants will be adult patient 
admitted with AP. Participants will undergo assessment at 
recruitment, 3 months and 3 years. At each time point, multiple 
biochemical and/or physiological assessments to measure 
cardiovascular, respiratory, liver, renal and cognitive function, 
diabetes mellitus and quality of life. Recruitment was from 30 
November 2017 to 31 May 2020; last follow- up measurements 
is due on 31 May 2023. The primary outcome measure is 
the incidence of new- onset type 3c diabetes mellitus during 
follow- up. Secondary outcome measures include: quality of 
life analyses (SF-36, Gastrointestinal Quality of Life Index); 
montreal cognitive assessment; organ system physiological 
performance; multiomics predictors of AP severity, detection of 
premature cellular senescence. In a nested cohort within the 
main cohort, individuals may also consent to multiparameter 
MRI scan, echocardiography, pulmonary function testing, 
cardiopulmonary exercise testing and pulse- wave analysis.
Ethics and dissemination This study has received the 
following approvals: UK IRAS Number 178615; South- east 
Scotland Research Ethics Committee number 16/SS/0065. 
Results will be made available to AP survivors, caregivers, 
funders and other researchers. Publications will be open- 
access.
Trial registration numbers  ClinicalTrials. gov Registry 
(NCT03342716) and ISRCTN50581876; Pre- results.
INTRODUCTION
Acute pancreatitis (AP) is an inflammatory 
disease of the pancreas usually triggered by 
gallstones or excess alcohol consumption. 
The incidence of AP ranges from 13 to 45 
per 100.00 individuals, is increasing,1 and 
varies between nations. For example, USA, 
Finland, Scotland and Germany report 
higher incidences than England and The 
Netherlands.2–5 AP triggers a cascade of 
inflammatory events causing cell damage 
and release of damage- associated molecular 
patterns that trigger inflammation and cyto-
kine release, initiating a systemic inflamma-
tory response resulting in multiple organ 
dysfunction syndrome (MODS) in one in 
five individuals. AP- MODS has a 21% fatality 
rate during the index episode, and overall 
in- hospital mortality is 5.2% in Scotland.6 7 
AP is graded into mild, moderate and severe, 
based on local and systemic determinants 
of severity as per the most recent AP classi-
fications (Determinant- based Classification8 
and Revised Atlanta Classification).9 Organ 
failure in AP most commonly affects the 
respiratory, renal and cardiovascular systems, 
but can involve any system.10 The pattern 
of organ failure is difficult to predict and a 
high level of inter- individual variance is seen, 
regardless of the aetiology. The molecular 
Strengths and limitations of this study
 ► Prospective cohort study with molecular mechanis-
tic observations.
 ► In- depth clinical and physiological annotation of 
multiomics data.
 ► Drop- out rates in long- term prospective acute pan-
creatitis (AP) studies is largely unknown.
 ► Potential participants with severe AP may lack ca-
pacity for consent and recruitment may therefore be 
slower in this group.
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mechanisms that explain this inter- individual variation in 
local and systemic inflammatory processes in AP remain 
unidentified.11 Multiomics analysis of serial time course 
blood samples has defined molecular patterns in human 
AP, called endotypes, but the precise relevance of these 
endotypes to clinical and therapeutic decision- making is 
not yet determined.12
Recently published data from a retrospective analysis of 
patients with AP has shown that the early development of 
MODS is associated with an increased mortality rate up 
to 10 years after the index presentation.6 This strongly 
suggests that MODS in acute pancreatitis (AP- MODS) has 
a persistent and deleterious impact on patients’ physio-
logical status, though the exact nature of this pathology 
remains to be characterised. Existing studies indicate that 
most deaths are the result of cardiovascular, pulmonary, 
digestive or malignant disease.13–16 In addition, the new 
onset of diabetes (type 3c diabetes mellitus (DM)) or 
impaired glucose tolerance, peripheral neuropathy and 
exocrine dysfunction have been documented as sources 
of morbidity in the years following the index attack of 
severe AP.16 17 Patients with alcohol- induced pancreatitis 
may be at particularly increased risk of progression to 
chronic pancreatitis,14 however the development of long- 
term complications is likely to be influenced by multiple, 
and as- yet unconfirmed, factors.
The aim of this observational clinical cohort study is to 
characterise the nature and extent of the pathophysiolog-
ical impact of severe AP on organ function over the first 
3 years after the index AP episode and define the long- 
term deleterious effect of severe AP. This will be achieved 
by prospectively measuring organ system function in 
patients recruited during a hospital admission with AP 
and at set time intervals thereafter. We will obtain an 
in- depth assessment of patients’ health at presentation, 
and at 3 months and 36 months after the first episode 
of AP using markers of organ function and/or disease in 
the peripheral blood. In a nested cohort within the main 
study cohort, we will conduct cardiorespiratory evalua-
tion tests (including exercise testing), specialised blood 
tests of the immune system, tests for precision medicine, 
and imaging to assess structure and function of key organ 
systems.
The results of this study will inform the design of future 
interventions designed to improve the long- term prog-
nosis of patients.
METHODS
Ethical approval
The study will be conducted in accordance with the 
principles of the International Conference on Harmon-
isation Tripartite Guideline for Good Clinical Practice. 
This study has been reviewed and been given a favour-
able opinion by the South- East Scotland Research 
Ethics Committee, under the application numbers: REC 
Number 16/SS/0065; IRAS Number 178615 and R&D 
approval Lothian R&D Number 2016/0152.
Study design
This is an observational prospective nested cohort study. 
The overall cohort is the population presenting with AP 
that meets the eligibility criteria. For the nested cohort of 
the study, a stratified block design is to be used to recruit 
equivalent numbers of patients with AP- MODS vs AP 
without MODS.
Setting
Single centre academic hospital setting—Royal Infir-
mary of Edinburgh, NHS Lothian and the Edinburgh 
Clinical Research Facility, Royal Infirmary of Edinburgh, 
UK.
Duration
Recruitment started on 30 November 2017 and is sched-
uled to end on 31 May 2020. The cohort assessment will 
comprise of three study visits. In- depth assessments of a 
participant’s health at presentation, at 3 months and at 
36 months follow- up study visit will be obtained. Addi-
tional cardiorespiratory evaluation tests, specialised 
blood tests of the immune system, tests for precision 
medicine, and imaging to assess structure and function 
of key organ systems will be conducted in a nested cohort 
of participants.
Intervention
This is a prospective study examining patient outcomes 
and trends in patients’ physiological status after an index 
event. Therefore, no intervention or randomisation is 
proposed.
Measurements
Primary endpoint
 ► Overall cohort: to define the incidence of new- onset 
type 3c DM in patients with AP, compared with the 
age- matched population of Scotland.
 ► Nested cohort: to define the baseline change in 
pancreatic fibrosis index measured by multiparam-
eter MRI between 3 months and 36 months after 
recruitment.
Secondary endpoints
Secondary end- points in the study will be experimental 
and observational, and will define explicitly, or be prelim-
inary exploratory studies investigating:
1. Genomic predictors of AP severity and resolution of 
inflammation.
2. miRNA signatures of disease severity and resolution.
3. Metabolomic profiling of AP resolution, and develop-
ment of local and systemic complications.
4. Premature cellular senescence as a pathological conse-
quence of AP- MODS.
5. Alteration in immune cell subsets and phenotype as a 
long- term response to AP- MODS.
6. Cardiovascular and respiratory dysfunction as a legacy 
of endothelial injury during AP- MODS.
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Summary of clinical data to be collected
All participants in the overall and nested cohorts will have 
the following data collected:
1. Demographic and clinical background information.
2. Information regarding the acute presentation.
3. Organ function assessment at recruitment, 3- month 
and 36- month follow- up study visit:
a. Overall cohort:
i. Full peripheral venous blood profiling, including 
cardiac biomarkers, standard biochemistry profil-
ing, and samples retained for miRNA profiling, cy-
tokines, telomere length, metabolomic profiling, 
proteomic profiling, transcriptomic profiling, ge-
nomic profiling, leucocyte subset analysis by flow 
cytometry.
ii. Biochemical markers of organ function in urine 
and samples retained.
iii. Pancreatic exocrine function test in stool (faecal 
elastase).
iv. Nutritional assessment.
v. Oral glucose tolerance test at 3- month and 
36- month follow- up study visit (with the exception 
of insulin dependent diabetics who will have ran-
dom blood glucose measured only).
vi. 12 lead ECG, blood pressure.
vii. Peripheral SpO2.
viii. Sway balance app non- invasive muscle function 
tests, 6- minute walk test.
ix. Self- administered Patient Questionnaire
1. Gastrointestinal Quality of Life Index.
2. SF-12 Quality of Life.
3. Montreal Cognitive Assessment.
b. Nested cohorts:
i. Pulse wave analysis (with salbutamol inhaler); 
transthoracic echocardiography.
ii. Spirometry and gas transfer.
iii. Cardiopulmonary exercise (CPEX) testing.
iv. Multiparameter MRI assessment of liver and 
pancreas.
Venous blood, urine and stool sampling
Blood samples will be obtained from each study partici-
pant at each of the three study visits for organ function 
and specialist assays. A urine sample and a stool sample 
will be obtained at each of the three visits.
Nutritional assessment
Participants will have their height and weight measured 
in order to calculate their body mass index, as well as 
bioimpedance analysis±upper arm anthropometry to 
assess percentage body fat and lean tissue mass. Partici-
pants will also be asked to keep a 24 hours food diary to 
assess whether their calorie and protein intake is suffi-
cient for their nutritional needs at all three study visits. 
Trace element, including zinc, selenium and vitamin B12 
levels and other relevant micronutrients will be measured 
in peripheral venous blood.
Oral glucose tolerance test
At the 3- month and 36- month follow- up study visits an 
oral glucose tolerance test will be performed. Participants 
attending the research site for physiological testing will 
be asked to attend in a fasted state. On arrival participants 
will have the baseline blood sample taken (using the 
same venepuncture as other tests above as appropriate), 
be given a standard 75 g anhydrous glucose in cold water 
or Polycal (113 mL) which is more palatable and will 
be followed by 150 mL water (total volume should be 
250–300 mL). After 120 min, a second blood sample will 
be taken (using the same venepuncture as other tests 
above as appropriate) to measure blood glucose.
An oral glucose tolerance test will not be performed 
in participants with insulin dependent diabetes. Instead a 
random glucose sample will be taken at these visits.
Non-invasive muscle function testing, Sway balance test, 6-minute 
walk test
Manual Muscle Testing will be performed once per visit to 
assess muscle strength. This will follow structured proto-
cols used to assess muscle strength in survivors of critical 
illness.18 The strength of muscles involved in shoulder 
abduction, elbow flexion, wrist extension, hip flexion, 
knee extension and ankle dorsiflexion will be graded 
according to the Medical Research Council muscle 
strength scoring system.
Participants will undergo an assessment of balance and 
postural stability at each visit. Testing will follow a vali-
dated protocol using the Sway Balance mobile testing 
system.19 20 Participants will be asked to hold a mobile 
device against their chest while completing a series of 
stances: standing with both feet together, standing with 
one foot behind the other, and standing on each leg in 
turn.20 Each stance is held for 10 s with the eyes closed. 
The Sway Balance application will generate a balance 
score, based on detection of alterations in position during 
each stance.
A 6- minute walk test will be done, according to stan-
dard protocols.21
Multiparameter MRI (liver and pancreas)
A multiparameter MRI scan will be performed on each 
visit for the nested cohort to measure lipid, iron load and 
fibrosis in liver and pancreas according to protocols in 
development at Clinical Research Imaging Centre. The 
total duration of scan will be approximately 30 min.
Cardiovascular analysis
Nested cohort participants will undergo pulse wave anal-
ysis at the radial artery using a non- invasive tonometer to 
measure wave reflection, pulse pressure and derived arte-
rial stiffness with the augmentation index at 75 beats/min 
and the administration of two puffs of inhaled salbutamol 
(200 µg each puff) via a spacer device. Transthoracic 
echocardiography will be performed to measure longitu-
dinal shortening of the myocardium.
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Pulmonary function testing and gas transfer
Spirometry will be undertaken in accordance with guid-
ance from the British Thoracic Society for the nested 
cohort group.22 All measurement will be made with 
participants seated. Forced expiratory volume in 1 second 
(FEV1) and forced vital capacity (FVC) will be recorded as 
the best of three consistent readings, and compared with 
the predicted normal values for the participant’s height, 
age, gender and ethnicity. Flow volume measurements 
will also be obtained. Lung volumes will be measured 
using the steady state method.22 Gas transfer/diffusion 
capacity will be measured using the single breath carbon 
monoxide transfer factor method.22
Cardiopulmonary exercise testing (CPEX)
CPEX testing will be carried out on day 2 of patient assess-
ment at all visits for nested cohort participants. Partici-
pants will be asked not to smoke for 8 hours prior to the 
test, and to abstain from other strenuous exercise on the 
same day.
Supervised CPEX testing will be conducted following 
a standardised incremental protocol on a magneti-
cally braked cycle ergometer. Work- load ramp will be 
determined using a standard formula.23 Testing will be 
continued until symptomatic limitation, volitional termi-
nation, failure to maintain required cadence or if other 
early termination conditions are met.24 Breath by breath 
O2 and CO2 analysis will be performed using a fully cali-
brated metabolic cart. Twelve- lead ECG and O2 satura-
tions will be monitored continuously in the pre- test, test 
and recovery phase. Non- invasive blood pressure will be 
recorded at rest and at 3- minute intervals during test 
and recovery phase. The anaerobic threshold (AT) will 
be independently determined by two assessors using the 
V- slope method.
Recruitment
All adult patients that meet the inclusion criteria at 
the participating sites will be recruited where possible. 
Patients admitted with an elevated serum amylase will 
be identified and members of the clinical research team 
will screen these patients for a diagnosis of AP using the 
TRAKCare management system (InterSystems, Massachu-
setts, USA). Potential participants will be approached 
by a member of the direct care team to confirm if they 
are willing to discuss the research with a member of 
the research team. If the individual agrees, they will be 
contacted by a member of the research team during their 
inpatient stay. If potential participants are discharged 
before they can be approached, they will not be included 
in the study
Inclusion criteria
The following inclusion criteria will apply to all patients:
1. Confirmed clinical or radiological diagnosis of AP with 
an elevated serum amylase greater than 300 U/L.
2. For the potential clinical diagnosis of AP an appro-
priate clinical history based on compatible clinical 
features, will be required (ie, abdominal pain, nausea 
and/or vomiting), supported by the finding of elevat-
ed serum amylase greater than 300 U/L. For the radio-
logical diagnosis, if applicable, CT and/or ultrasound 
scan (USS) evidence of AP will be accepted.
Exclusion criteria
1. Patients under 16 years of age.
2. Prisoners.
3. Any patient that lacks capacity to consent.
The additional two exclusions below apply only to 
those patients being considered for the nested cohort 
study:
4. Patients not able to undergo MRI scanning for techni-
cal reasons will be excluded (eg, those with cochlear 
implants, implanted pacemaker)
5. Patients with a known allergy to salbutamol
Co- enrolment to other research studies, including 
drug, interventional and long- term follow- up studies, will 
be permitted if this has been agreed and documented by 
the Chief Investigators of co- enrolling studies.
Statistical analysis plan
Full details of the statistical analysis will be documented 
in the statistical analysis plan developed prior to any anal-
ysis. Any deviations from this will be documented. We will 
present the data descriptively, where data is categorical 
numbers and percentages will be presented and where 
data is continuous number, mean, SD, median, 25th 
centile, 75th centile, min and max will be presented. 
Annual incidence of type 3 c diabetes will be given as a 
percentage with an accompanying 95% CI. For the nested 
cohort we will present the change in fibrosis index over 
time graphically with accompanying descriptive statis-
tics, and where appropriate include details of the index 
episode including aetiology, severity and pre- existing 
medical background as covariates wherever possible. 
Quality of assessment will be included as a potential 
confounder.
Sample size calculation
Overall sample size calculation has been performed to 
illustrate how well we will be able to estimate the annual 
incidence of type 3c diabetes in patients with AP with 
varying sample sizes.25 26 The incidence of type 3c DM 
was chosen for the purposes of establishing a prospective 
cohort size because it is specific, measurable, clinically 
relevant and offers a practice- changing opportunity for 
intervention. With a sample of 323 we would have 80% 
power to be able to show a difference from the incidence 
of DM in the general population (6%) if we observed an 
incidence in the cohort of 10% or greater. Moreover, this 
sample size will support the evaluation of the secondary 
endpoints, allowing us to adjust for any confounding 
factors.
Nested cohort sample size has been calculated to detect 
the difference in the 3 months to 36 months change in 
pancreatic fibrosis index between those with AP with 
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MODS and those with AP without MODS based on 
Banerjee et al estimates of fibrosis index using multipa-
rameter MRI.27 Based on a sample size of 20 participants 
per group, using a two- sided two- sample test with a 5% 
level of significance and 80% power, we would be able to 
detect an effect size of 0.909 (where the effect size is the 
absolute difference in means divided by common SD). 
To allow for potential dropouts in this part of the study 
(death, withdrawal) a minimum sample size of 25 individ-
uals will be recruited for the nested cohort.
Data management
Data will be collected either directly onto an electronic case 
report form on Research Electronic Data Capture tools 
hosted at University of Edinburgh28 29 or onto paper data 
collection sheets which will be entered onto the electronic 
form at site. All participants will be allocated a unique study 
number which will be used in all electronic and paper data 
collection tools. The study link- anonymised data will be stored 
on secure password- protected, regularly backed- up, comput-
erised storage in accordance to secure data protection princi-
ples of the University of Edinburgh/clinical research facility 
(CRF) at study sites.
Personal contact details and the Community Health Index 
(CHI) number are required for follow- up and tracking elec-
tronic health records, and will initially be kept on paper at 
participating sites in a secure storage area with restricted 
access. These details will ultimately be stored on an encrypted 
database within NHS Lothian. Personal contact details and 
CHI numbers will not be entered onto the study database.
The chief investigator (DJM) will have access to the data 
during all stages of the study. The analysis will be performed 
in secure premises at the University of Edinburgh and NHS 
Lothian by the chief investigator and the assigned statisti-
cian. The chief investigator will have control of and act as the 
custodian for the data generated by the study.
Participants
Consent
Potential study participants will be provided with a written 
information sheet and a written consent form. In addition, 
participants will meet with a member of the CRF team to 
receive a full explanation of the nature and purpose of the 
study, with the opportunity to ask questions. It will be made 
clear that the individual may withdraw from the study at 
any time without giving a reason and with no consequence 
to their current or future care. Recruitment and informed 
consent will be performed by the investigator/member of 
the CRF team at the participating site. If individuals wish to 
participate, they will sign a consent form, countersigned by 
the investigator/CRF researcher. In addition, consent will be 
obtained to inform the participants’ GP and Consultant in 
charge of their care.
Patient decision period
Potential participants who have been invited to participate 
will be given a period of up to 2 days (minimum 1 hour) to 
read the relevant information sheets, to contact a member of 
the study team to get further information and ask questions, 
before they are invited to participate in a conversation and 
commence the process of fully- informed consent.
Withdrawal of participants
Participants will be withdrawn from the clinical research 
study in the following circumstances:
1. In cases of withdrawal of informed consent, where ca-
pacity exists.
2. In cases of withdrawal of consent by the participant’s 
representative for adults with incapacity.
Participants who wish to withdraw from the study will be 
given the option to permit ongoing use of data and samples 
that have already been collected, and/or future recording 
and usage of routinely collected clinical data and results. 
This will be clearly documented on the patient consent form. 
Patients that become uncontactable will have any previously 
collected data included in the study unless consent is with-
drawn as above.
Benefits to participants
No direct benefit is expected for the participants. We envisage 
that the results of this study will benefit other patients with 
AP in the future, and society as a whole by advancing scien-
tific knowledge on this condition. We believe that this study 
may lead to new strategies in the treatment of AP which will 
prevent or ameliorate the impact of organ dysfunction. This 
will help to maximise the health, and life expectancy, of 
patients with AP.
Potential burden to participants
The participants will be subjected to peripheral venous blood 
sampling which may cause discomfort or pain. In order to 
minimise these effects, blood sampling will be performed 
by appropriately trained and experienced members of the 
research team, in adherence to the local guidelines for blood 
sampling. Where possible, and only if the specific study 
venepuncture time- points coincide, clinical care samples will 
be taken at the same time to reduce the number of venepunc-
tures that any one participant sustains.
The collection of urine and stool samples is not expected 
to cause any harm or discomfort; however, some minimal 
inconvenience may be caused. In order to address this, a 
convenient time for the participants and the clinical care 
team will be chosen, and a full explanation of the purpose 
of these tests will be provided. The participants' dignity and 
privacy will be respected at all times.
The 6- minute walk test is not anticipated to cause any 
harm or discomfort to participants. Pulse wave analysis is not 
expected to cause any significant adverse effects. Inhaled 
salbutamol may cause a very slight peripheral tremor, but no 
other expected harm or discomfort.
CPEX testing is associated with a very low risk of serious 
complications; however, this is related to the severity of 
co- morbid disease such as coronary artery disease (CAD).24 
For those participants with identified CAD, the opinion of a 
cardiologist will be sought on the suitability of the participant 
for this test.
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Assessment of pulmonary function using spirometry is not 
known to be associated with any significant adverse events.30 
Participants may experience some discomfort or dizziness 
during the test due to the requirement for complete exha-
lation.31 Spirometry is associated with increased myocardial 
strain, and a rise in intrathoracic, intraabdominal and intra-
ocular pressures, and consequently will not be performed on 
participants with the following: recent head/neck, thoracic 
or abdominal surgery, recent myocardial infarction, retinal 
detachment, resting pulse greater than 120 beats/min, preg-
nant, severe heart failure or arrhythmia, pneumothorax, 
aortic or cerebral aneurysm.32
MRI scans are not expected to pose risks to the majority 
of participants, in the absence of known contraindications. 
Participants will be assessed prior to the scan for any poten-
tial contraindications to the procedure such as mechanical 
heart valves, pacemakers, metallic prostheses and cochlear 
implants.33
ETHICS AND DISSEMINATION
This study has been reviewed as IRAS Number 178 615 by 
the South- East Scotland Research Ethics Committee under 
the application numbers (REC Number) 16/SS/0065 and 
has been given a favourable opinion. NHS Scotland R&D 
approval have been granted. The study sponsor is NHS 
Lothian/University of Edinburgh ACCORD.
Results of the study will be presented at local, national and 
international medical meetings. The findings of the study 
will be published in peer- reviewed medical/scientific jour-
nals and made open- access on acceptance. If appropriate, 
the results of the study will be disseminated via press releases 
by the University of Edinburgh. Information may also be 
disseminated to the general public via public engagement 
and community outreach programmes.
Patient and public involvement
Patients who have had an episode of AP and who partic-
ipate in the acute pancreatitis patient liaison group were 
invited to input and contributed to the concepts and the 
trial design.
Versioning
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